Shares of Henry Schein, Inc. (NASDAQ:HSIC – Get Free Report) have earned an average recommendation of “Moderate Buy” from the twelve brokerages that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, five have given a hold recommendation, five have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $77.10.
A number of analysts have issued reports on HSIC shares. UBS Group reduced their target price on shares of Henry Schein from $75.00 to $72.00 and set a “neutral” rating for the company in a research note on Wednesday, August 7th. Piper Sandler reiterated an “overweight” rating and issued a $86.00 target price on shares of Henry Schein in a research note on Friday, June 21st. Evercore ISI reduced their price objective on shares of Henry Schein from $72.00 to $70.00 and set an “in-line” rating for the company in a research note on Wednesday, August 7th. Baird R W upgraded shares of Henry Schein from a “hold” rating to a “strong-buy” rating in a research note on Monday, July 22nd. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Henry Schein from $88.00 to $80.00 and set an “overweight” rating for the company in a research note on Monday, August 12th.
Check Out Our Latest Analysis on Henry Schein
Henry Schein Stock Performance
Henry Schein (NASDAQ:HSIC – Get Free Report) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $1.23 EPS for the quarter, beating analysts’ consensus estimates of $1.22 by $0.01. Henry Schein had a net margin of 2.82% and a return on equity of 13.19%. The firm had revenue of $3.10 billion for the quarter, compared to the consensus estimate of $3.27 billion. During the same period in the previous year, the firm posted $1.31 earnings per share. The firm’s revenue was up .0% on a year-over-year basis. As a group, equities research analysts predict that Henry Schein will post 4.74 EPS for the current year.
Insider Activity at Henry Schein
In related news, SVP Lorelei Mcglynn sold 21,035 shares of the company’s stock in a transaction on Friday, September 6th. The shares were sold at an average price of $69.30, for a total transaction of $1,457,725.50. Following the completion of the transaction, the senior vice president now directly owns 71,833 shares in the company, valued at $4,978,026.90. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 1.14% of the company’s stock.
Hedge Funds Weigh In On Henry Schein
Several large investors have recently bought and sold shares of the stock. GAMMA Investing LLC increased its holdings in Henry Schein by 106.7% in the 3rd quarter. GAMMA Investing LLC now owns 2,069 shares of the company’s stock valued at $151,000 after buying an additional 1,068 shares during the period. Czech National Bank increased its holdings in Henry Schein by 5.8% in the 3rd quarter. Czech National Bank now owns 25,811 shares of the company’s stock valued at $1,882,000 after buying an additional 1,409 shares during the period. Handelsbanken Fonder AB increased its holdings in Henry Schein by 41.9% in the 3rd quarter. Handelsbanken Fonder AB now owns 34,900 shares of the company’s stock valued at $2,544,000 after buying an additional 10,300 shares during the period. SG Americas Securities LLC increased its holdings in Henry Schein by 1,622.3% in the 3rd quarter. SG Americas Securities LLC now owns 458,828 shares of the company’s stock valued at $33,449,000 after buying an additional 432,187 shares during the period. Finally, Sanctuary Advisors LLC bought a new stake in Henry Schein in the 2nd quarter valued at $351,000. 96.62% of the stock is currently owned by institutional investors and hedge funds.
Henry Schein Company Profile
Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
Further Reading
- Five stocks we like better than Henry Schein
- Stock Market Upgrades: What Are They?
- Ciena Stock Powers the AI Cloud Boom—Don’t Miss Out
- NYSE Stocks Give Investors a Variety of Quality Options
- Affirm’s Path to Profitability Elevates with Interest Rate Cuts
- What is the Nikkei 225 index?
- RPM International Thrives in Rate-Cut Driven Construction Rally
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.